Basel, Switzerland (ots/PRNewswire) - - FDA Grants Fast Track Status to R1626 Roche announced today the start of the first phase II development study to evaluate R1626, their promising new polymerase inhibitor, for the treatment of hepatitis C. The investigational drug has also been granted Fast Track ...
Basel (ots/PRNewswire) - - Results Unveiled at ICAAC Show That Over 90% of Treatment-Experienced Patients Achieve Treatment Goal of Undetectable Viral Load Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) ...
Basel, Switzerland (ots/PRNewswire) - - First Treatment for Years to Have Shown a Significant Survival Benefit for Patients Roche announced today that it has requested a re-examination of the data supporting the filing of their breakthrough cancer medicine, Tarceva, for the treatment of pancreatic cancer ...
Basel, Switzerland (ots/PRNewswire) - - FUZEON Combined With New Protease Inhibitors Provides Best Hope for Patients who Have Been Battling Resistant Virus During the world's largest HIV/AIDS congress in Toronto (XVI International AIDS Conference) new guidelines from the influential International AIDS ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its cancer medicine Tarceva (erlotinib) has received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in combination with gemcitabine chemotherapy for the first line treatment of advanced pancreatic ...
Basel, Switzerland (ots/PRNewswire) - The US approval of TMC114 (darunavir), a new boosted protease inhibitor (PI), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON (enfuvirtide) that can successfully combat the HIV virus in treatment resistant patients. ...
Basel, Switzerland and Amsterdam (ots/PRNewswire) - - First RA Drug to Achieve These Results in Patients With an Inadequate Response to Currently Available Treatments New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly ...
Basel, Switzerland (ots/PRNewswire) - - Newest HIV Drug Works Better in Combination With FUZEON(R) The emergence of new HIV treatments, such as boosted protease inhibitors (PI), has led to a change in treatment goals for people living with drug-resistant HIV. Up until recently, it has been reluctantly ...
Basel, Switzerland (ots/PRNewswire) - A new study(1) suggests that treatment with the combination of the innovative cancer drugs Avastin (bevacizumab) and Tarceva (erlotinib) or Avastin with chemotherapy, improves progression-free survival in patients with recurrent or refractory non-small cell lung cancer ...
Basel, Switzerland (ots/PRNewswire) - - Real World Practice Confirms Avastin's Efficacy and Safety in Advanced Colorectal Cancer New data from 4,000 patients show that Avastin (bevacizumab rhuMAb-VEGF) enables patients with advanced colorectal cancer (CRC) to live longer without progression of their ...
Basel, Switzerland (ots/PRNewswire) - - Important Step Towards Broad Access of Herceptin for Women With Aggressive Form of Breast Cancer Roche today announced that the European Union's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Herceptin following surgery and standard chemotherapy as adjuvant treatment ...
Zurich, Suisse (ots/PRNewswire) - - Knowledge Gap of Concern to Both Physicians and Patient Groups Nine out of ten patients battling cancer in Europe have never heard of a major breakthrough in cancer treatment, known as anti-angiogenesis, according to a new survey released today. Yet, 70% of cancer ...
Basel, Switzerland and Morrisville, North Carolina (ots/PRNewswire) - - Early Preclinical Data on TR-291144 and TR-290999 to be Presented at Major HIV Congress in February BASEL, Switzerland and MORRISVILLE, North Carolina, January 19 /PRNewswire/ -- Roche and Trimeris today announced their collaboration ...
Basel, Switzerland (ots/PRNewswire) - - Power of "FUZEON effect" Provides Much Needed Hope for HIV Patients Facing Treatment Failure Exciting interim data presented at the annual ICAAC(i) conference show that adding FUZEON (enfuvirtide) to the investigational boosted protease inhibitor (PI), TMC114/r, more than doubles the proportion of patients reaching ...
Dublin, Ireland, November 18 (ots/PRNewswire) - - Latest Advances in Health Psychology may Help Physicians Implement Improved HIV Care - News From 10th European AIDS Conference, Dublin, Ireland Initial results from the OpenMind study, the largest behavioural study to look at both patients' and ...
San Diego, California, November 17 (ots/PRNewswire) - - First Phase III Data Presented at the ACR Annual Meeting Roche today announced the results of the first Phase III study in rheumatoid arthritis (RA) conducted by Chugai in Japan which are being presented at the American College of Rheumatology (ACR) ...
Basel, Switzerland (ots/PRNewswire) - The news that the innovative new cancer drug Tarceva(R) (erlotinib) is now becoming available across the EU will provide a glimmer of hope to over 380,000 people in Europe this year who have received the devastating news that they have lung cancer. Not only has Tarceva demonstrated a striking survival benefit (42.5 per ...
Basel, Switzerland (ots/PRNewswire) - Following today's European approval of Boehringer Ingelheim's boosted protease inhibitor tipranavir (APTIVUS(R)), European patients now have the chance to benefit from the potent combination of the fusion inhibitor FUZEON (enfuvirtide) and boosted tipranavir in addition to ...
Basel, Switzerland (ots/PRNewswire) - - New potent combinations make suppression of virus to undetectable levels more achievable for treatment-experienced HIV patients The importance of the drug FUZEON(R) (enfuvirtide) in the management of HIV has been officially recognised by the US Department of Health ...
Rio De Janeiro, Brazil (ots/PRNewswire) - - Giving Patients Facing HIV Resistance Their Best Chance to Achieve Undetectable Viral Loads Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing resistance their best chance of achieving undetectable viral load - the optimal treatment goal for all people living with ...
Basel, Switzerland (ots/PRNewswire) - - Results Provide New Hope in Fight Against One of the Most Deadly Cancers Treatment with the innovative cancer drug Tarceva(R) in patients with advanced non-small cell lung cancer (NSCLC) resulted in significantly longer survival compared to placebo (42.5% ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative, oral cancer medicine Tarceva (erlotinib) has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of non-small cell lung cancer, the most common form of lung cancer. "This decision is proof of the impressive ...
Barcelona, Spain (ots/PRNewswire) - The addition of Avastin(R) (bevacizumab, rhuMAb-VEGF) to chemotherapy increases the survival of patients with advanced colorectal cancer while also preserving their quality of life for longer according to new data presented today at the 7th World Congress on Gastrointestinal ...
Basel, Switzerland (ots/PRNewswire) - The addition of Tarceva(tm) (erlotinib) to chemotherapy extends survival by 23.5% for patients with advanced pancreatic cancer, according to data presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, USA.(1) Tarceva, an advanced new cancer drug taken as a once-daily tablet, has already demonstrated a clear survival benefit for patients with ...
Basel, Switzerland (ots/PRNewswire) - - Anti-Angiogenic Treatment Shows Survival Benefit Across Three Major Cancer Types: Breast, Lung And Colorectal Cancer A new study with Avastin(R) (bevacizumab, rhuMAb-VEGF) today reported that when used in combination with chemotherapy, Avastin doubled the chances of ...
Basel, Switzerland (ots/PRNewswire) - - Addition of Avastin Boosts Efficacy of First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer A new study, presented for the first time today, reveals that Avastin(R) (bevacizumab rhuMAb-VEGF) significantly extends survival for patients with previously untreated, advanced non-small cell lung cancer (NSCLC), ...
Basel, Switzerland (ots/PRNewswire) - - New Study Published Today Provides Further Evidence of the Benefit of Avastin(R) for Patients With Advanced Colorectal Cancer Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps ...
Basel, Switzerland (ots/PRNewswire) - - Study adds to the body of evidence showing the benefits of Avastin with different colorectal cancer treatment regimens A new study, presented for the first time today, shows Avastin(R) (bevacizumab, rhuMAb-VEGF) significantly increases survival in patients with ...
Basel, Switzerland (ots/PRNewswire) - - New data shows significant improvement in overall survival when Tarceva is added to chemotherapy New data, presented for the first time today, have shown that adding Tarceva (erlotinib) to chemotherapy improves survival in patients with locally advanced or metastatic pancreatic cancer(1). This is the second cancer type ...
Basel, Switzerland (ots/PRNewswire) - - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer Roche today announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer. Roche will now make Avastin available ...